Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma

NCT05813470 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

256

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Asthma
Uncontrolled Moderate to Severe

Interventions

BIOLOGICAL: Omalizumab (CinnaGen)
BIOLOGICAL: Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)

Sponsor

Cinnagen